Recursion Pharmaceuticals, Inc.
RXRX
$4.51
$0.194.28%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -89.42% | -73.14% | -62.31% | -41.33% | -29.12% |
| Total Depreciation and Amortization | 148.18% | 101.20% | 72.71% | 49.55% | 54.99% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 123.58% | 134.69% | 102.37% | 60.25% | 56.90% |
| Change in Net Operating Assets | 116.37% | 158.95% | 88.12% | 24.39% | -39.74% |
| Cash from Operations | -38.81% | -15.54% | -22.75% | -24.81% | -22.97% |
| Capital Expenditure | 54.90% | -1.83% | 33.94% | -14.55% | 19.05% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 390,387.32% | 390,387.32% | 14,927.33% | 14,927.33% | -103.71% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -88.48% | -35.77% | -9,162.50% | -2,763.25% | -1,537.77% |
| Cash from Investing | 1,552.78% | 1,986.00% | 2,348.00% | 2,642.62% | -13.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -175.60% | -1,006.36% | -741.28% | -479.63% | -3,092.63% |
| Issuance of Common Stock | 9.11% | -57.11% | 120.58% | 118.99% | 82.36% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6.96% | -59.83% | 117.44% | 117.02% | 80.98% |
| Foreign Exchange rate Adjustments | 6,471.05% | 3,459.45% | 5,775.86% | -1,911.70% | 178.19% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 498.89% | -22.50% | 215.20% | 227.85% | 157.07% |